H.C. Wainwright analyst Edward White raised the firm’s price target on TG Therapeutics to $34 from $28 and keeps a Buy rating on the shares as the firm is increasing its sales estimates for Briumvi after the company reported Q1 results. TG reported Briumvi sales of $7.8M, compared to the firm’s estimate of $3M and the consensus of $3.4M, says H.C. Wainwright, which calls the drug’s launch "impressive."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- TG Therapeutics reports Q1 EPS (28c), consensus (37c)
- TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
- TG Therapeutics announces issuance of permanent J-code for BRIUMVI
- TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
